CN109646423A - Boiomacromolecule nanosphere containing NADH and the preparation method and application thereof - Google Patents
Boiomacromolecule nanosphere containing NADH and the preparation method and application thereof Download PDFInfo
- Publication number
- CN109646423A CN109646423A CN201811465156.1A CN201811465156A CN109646423A CN 109646423 A CN109646423 A CN 109646423A CN 201811465156 A CN201811465156 A CN 201811465156A CN 109646423 A CN109646423 A CN 109646423A
- Authority
- CN
- China
- Prior art keywords
- boiomacromolecule
- nadh
- nanosphere
- carrier
- parts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 title claims abstract description 165
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 title claims abstract description 158
- 239000002077 nanosphere Substances 0.000 title claims abstract description 85
- 238000002360 preparation method Methods 0.000 title abstract description 36
- 239000002245 particle Substances 0.000 claims abstract description 28
- 239000003826 tablet Substances 0.000 claims abstract description 21
- 239000002775 capsule Substances 0.000 claims abstract description 17
- 239000007901 soft capsule Substances 0.000 claims abstract description 14
- -1 NADH small molecule Chemical class 0.000 claims abstract description 12
- 239000003814 drug Substances 0.000 claims abstract description 11
- 239000000203 mixture Substances 0.000 claims abstract description 11
- 229940079593 drug Drugs 0.000 claims abstract description 9
- 235000013376 functional food Nutrition 0.000 claims abstract description 7
- 230000004048 modification Effects 0.000 claims abstract description 6
- 238000012986 modification Methods 0.000 claims abstract description 6
- 239000000463 material Substances 0.000 claims description 68
- 229920002752 Konjac Polymers 0.000 claims description 35
- LUEWUZLMQUOBSB-FSKGGBMCSA-N (2s,3s,4s,5s,6r)-2-[(2r,3s,4r,5r,6s)-6-[(2r,3s,4r,5s,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5s,6r)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](OC3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-FSKGGBMCSA-N 0.000 claims description 31
- 229920002581 Glucomannan Polymers 0.000 claims description 31
- 229940046240 glucomannan Drugs 0.000 claims description 31
- 238000000034 method Methods 0.000 claims description 29
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 29
- 238000005469 granulation Methods 0.000 claims description 25
- 230000003179 granulation Effects 0.000 claims description 25
- 230000001070 adhesive effect Effects 0.000 claims description 18
- 229920001661 Chitosan Polymers 0.000 claims description 17
- 239000000853 adhesive Substances 0.000 claims description 17
- 239000000080 wetting agent Substances 0.000 claims description 15
- 235000010413 sodium alginate Nutrition 0.000 claims description 13
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 9
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 9
- 229920001285 xanthan gum Polymers 0.000 claims description 9
- 239000000230 xanthan gum Substances 0.000 claims description 9
- 235000010493 xanthan gum Nutrition 0.000 claims description 9
- 229940082509 xanthan gum Drugs 0.000 claims description 9
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 8
- 239000008187 granular material Substances 0.000 claims description 8
- 238000000227 grinding Methods 0.000 claims description 8
- 239000000661 sodium alginate Substances 0.000 claims description 8
- 229940005550 sodium alginate Drugs 0.000 claims description 8
- 239000003981 vehicle Substances 0.000 claims description 8
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 6
- 239000006187 pill Substances 0.000 claims description 6
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 6
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 5
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 5
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 5
- 239000002994 raw material Substances 0.000 claims description 5
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 239000008157 edible vegetable oil Substances 0.000 claims description 4
- 230000036541 health Effects 0.000 claims description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 229920001222 biopolymer Polymers 0.000 claims description 3
- 235000009508 confectionery Nutrition 0.000 claims description 3
- 239000010408 film Substances 0.000 claims description 3
- 239000007902 hard capsule Substances 0.000 claims description 3
- 239000007924 injection Substances 0.000 claims description 3
- 238000002347 injection Methods 0.000 claims description 3
- 239000006210 lotion Substances 0.000 claims description 3
- 235000019359 magnesium stearate Nutrition 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 239000000829 suppository Substances 0.000 claims description 3
- 239000006188 syrup Substances 0.000 claims description 3
- 235000020357 syrup Nutrition 0.000 claims description 3
- 229940098465 tincture Drugs 0.000 claims description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 2
- 239000011575 calcium Substances 0.000 claims description 2
- 229910052791 calcium Inorganic materials 0.000 claims description 2
- 229920000137 polyphosphoric acid Polymers 0.000 claims description 2
- 241000209094 Oryza Species 0.000 claims 2
- 235000007164 Oryza sativa Nutrition 0.000 claims 2
- 235000013339 cereals Nutrition 0.000 claims 2
- 235000009566 rice Nutrition 0.000 claims 2
- 239000000969 carrier Substances 0.000 claims 1
- 230000008961 swelling Effects 0.000 claims 1
- 229920000642 polymer Polymers 0.000 abstract description 15
- 239000000835 fiber Substances 0.000 abstract description 12
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract description 5
- 239000001301 oxygen Substances 0.000 abstract description 5
- 229910052760 oxygen Inorganic materials 0.000 abstract description 5
- 239000002861 polymer material Substances 0.000 abstract description 5
- 230000015572 biosynthetic process Effects 0.000 abstract description 2
- 238000004321 preservation Methods 0.000 abstract description 2
- 239000012798 spherical particle Substances 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 22
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 229920002521 macromolecule Polymers 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- 108010024137 Nicotinamide-Nucleotide Adenylyltransferase Proteins 0.000 description 7
- 102000015597 Nicotinamide-nucleotide adenylyltransferase Human genes 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 235000019441 ethanol Nutrition 0.000 description 7
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 6
- 229920002472 Starch Polymers 0.000 description 6
- 235000013325 dietary fiber Nutrition 0.000 description 6
- 229950006238 nadide Drugs 0.000 description 6
- 238000004088 simulation Methods 0.000 description 6
- 239000008107 starch Substances 0.000 description 6
- 235000019698 starch Nutrition 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 5
- 229920000881 Modified starch Polymers 0.000 description 5
- 238000002441 X-ray diffraction Methods 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 229920005615 natural polymer Polymers 0.000 description 5
- 239000002002 slurry Substances 0.000 description 5
- 239000000872 buffer Substances 0.000 description 4
- 210000001072 colon Anatomy 0.000 description 4
- 150000004676 glycans Chemical class 0.000 description 4
- 235000010485 konjac Nutrition 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 244000247812 Amorphophallus rivieri Species 0.000 description 3
- 235000001206 Amorphophallus rivieri Nutrition 0.000 description 3
- 239000006137 Luria-Bertani broth Substances 0.000 description 3
- DAYLJWODMCOQEW-TURQNECASA-N NMN zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)([O-])=O)O2)O)=C1 DAYLJWODMCOQEW-TURQNECASA-N 0.000 description 3
- 208000027089 Parkinsonian disease Diseases 0.000 description 3
- 206010034010 Parkinsonism Diseases 0.000 description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000000287 crude extract Substances 0.000 description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 3
- 239000000252 konjac Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 238000005215 recombination Methods 0.000 description 3
- 230000006798 recombination Effects 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 108010039224 Amidophosphoribosyltransferase Proteins 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 description 2
- 230000003064 anti-oxidating effect Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 235000005687 corn oil Nutrition 0.000 description 2
- 239000002285 corn oil Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 210000004211 gastric acid Anatomy 0.000 description 2
- 210000004051 gastric juice Anatomy 0.000 description 2
- 229930027917 kanamycin Natural products 0.000 description 2
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical class O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- DKXULEFCEORBJK-UHFFFAOYSA-N magnesium;octadecanoic acid Chemical compound [Mg].CCCCCCCCCCCCCCCCCC(O)=O DKXULEFCEORBJK-UHFFFAOYSA-N 0.000 description 2
- 235000020956 nicotinamide riboside Nutrition 0.000 description 2
- 239000011618 nicotinamide riboside Substances 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- 238000007873 sieving Methods 0.000 description 2
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 239000004132 Calcium polyphosphate Substances 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 102000011724 DNA Repair Enzymes Human genes 0.000 description 1
- 108010076525 DNA Repair Enzymes Proteins 0.000 description 1
- 108020005199 Dehydrogenases Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- JLEBZPBDRKPWTD-TURQNECASA-O N-ribosylnicotinamide Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](CO)O2)O)=C1 JLEBZPBDRKPWTD-TURQNECASA-O 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 229920001100 Polydextrose Polymers 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000003876 biosurfactant Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 235000019827 calcium polyphosphate Nutrition 0.000 description 1
- 239000010495 camellia oil Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 230000003930 cognitive ability Effects 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 150000002170 ethers Chemical group 0.000 description 1
- 125000005909 ethyl alcohol group Chemical group 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 239000008169 grapeseed oil Substances 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 230000029553 photosynthesis Effects 0.000 description 1
- 238000010672 photosynthesis Methods 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000001259 polydextrose Substances 0.000 description 1
- 235000013856 polydextrose Nutrition 0.000 description 1
- 229940035035 polydextrose Drugs 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000027756 respiratory electron transport chain Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/30—Foods or foodstuffs containing additives; Preparation or treatment thereof containing carbohydrate syrups; containing sugars; containing sugar alcohols, e.g. xylitol; containing starch hydrolysates, e.g. dextrin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
- A23L33/25—Synthetic polymers, e.g. vinylic or acrylic polymers
- A23L33/26—Polyol polyesters, e.g. sucrose polyesters; Synthetic sugar polymers, e.g. polydextrose
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/20—Agglomerating; Granulating; Tabletting
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/20—Agglomerating; Granulating; Tabletting
- A23P10/28—Tabletting; Making food bars by compression of a dry powdered mixture
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/30—Encapsulation of particles, e.g. foodstuff additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/30—Encapsulation of particles, e.g. foodstuff additives
- A23P10/35—Encapsulation of particles, e.g. foodstuff additives with oils, lipids, monoglycerides or diglycerides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P20/00—Coating of foodstuffs; Coatings therefor; Making laminated, multi-layered, stuffed or hollow foodstuffs
- A23P20/20—Making of laminated, multi-layered, stuffed or hollow foodstuffs, e.g. by wrapping in preformed edible dough sheets or in edible food containers
- A23P20/25—Filling or stuffing cored food pieces, e.g. combined with coring or making cavities
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
The invention discloses a kind of boiomacromolecule nanosphere containing NADH comprising boiomacromolecule carrier and the NADH being scattered on the boiomacromolecule carrier.The boiomacromolecule carrier is macromolecular fibre condensate; its fiber skeleton passes through the arrangement modes such as disorderly arranged, cross arrangement, curling arrangement; constitute three-dimensional interpenetrating polymer network structure; so that NADH is protected; it solves the problems, such as labile after it meets light or oxygen, extends the holding time of NADH effective component, reduces preservation difficulty.The invention also discloses the preparation processes of nanosphere, and by obtaining the bioabsorbable polymer material of medium-chain after physical modification, easily formation spherical particle, composition honeycomb three-dimensional interpenetrating polymer network structure are conducive to NADH small molecule and are carried on network structure surfaces externally and internally.Nanosphere can be used for preparing the preparations such as tablet, particle, capsule or soft capsule, as body-care or pet treat drug/functional food.
Description
Technical field
The invention belongs to health product technical field, relate in particular to a kind of boiomacromolecule nanosphere containing NADH and
Preparation method and application.
Background technique
The reduction-state of nicotinamide adenine dinucleotide (NADH) is a kind of coenzyme for transmitting proton, also referred to as reduced coenzyme
I, during active somatic cell hundreds and thousands of a metabolic responses, NADH has redox active, in sugared ferment as electron donor
Important Electron Transfer is played during solution, citrate cycle and photosynthesis etc..In vivo, NADH takes part in dimension
Process, the generation process of atriphos (ATP) derived from raw element, and be the auxiliary of identified more than 250 kinds of dehydrogenases out
Enzyme maintains cell growth, differentiation and energetic supersession.
NADH is considered to have the substance and without side-effects for increasingly increasing physical and intellectual performance effect, can be used for
The drug improved health conditions with quality of life, clinical research show that parenteral administration NADH presses down treatment Parkinson's disease and severe
Strongly fragrant disease has positive effect.NADH can promote parkinsonism, the cognitive ability of Alzheimer's and locomitivity, Yi Jihuan
Tired, drowsiness, pigmentosa fatigue syndrome is solved, user's vigor and power are enhanced.
The middle of last century, successful treatment parkinsonism, alzheimer's disease etc. are various by way of infusion by NADH
The nervous system disease and Delayed onset are dull-witted, but NADH medical fluid unstable chemcial property, instant need to match, so while this
The center of gravity of biomolecule activates and has obtained determination before stimulation characteristic 50 years, but since its is highly sensitive (non-to light and oxygen
It is often sensitive) and unstable feature, so that it is not used widely always.And divided immediately after being contacted due to NADH with gastric acid
Solution leads to not take orally.
Summary of the invention
For this purpose, technical problem to be solved by the present invention lies in NADH unstable chemcial property, be difficult to store, can not mouth
Clothes, to propose a kind of boiomacromolecule containing NADH for improving stability, being easy to save, is orally available, can be mass-produced
Nanosphere and the preparation method and application thereof.
In order to solve the above technical problems, the technical solution of the present invention is as follows:
The present invention provides a kind of boiomacromolecule nanosphere containing NADH comprising boiomacromolecule carrier and is scattered in institute
State the NADH on boiomacromolecule carrier.
Preferably, the boiomacromolecule carrier is in three-dimensional net structure, the average grain of the boiomacromolecule carrier
Diameter is 200-1000nm.
Preferably, the boiomacromolecule carrier be chitosan and/or konjaku glucomannan,
Preferably, the konjaku glucomannan is konjaku glucomannan, quaternized konjaku glucomannan, carboxy methyl konjaku Portugal
At least one of sweet glycan, deacetylated konjaku glucomannan.
Preferably, in parts by weight, the nanosphere includes 1-20 parts of NADH, 20-80 parts of bioabsorbable polymer materials,
Preferably, the nanosphere further includes auxiliary material, the auxiliary material in parts by weight, including 0.05-30 parts of sodium alginates
And/or 0.05-30 parts of xanthan gum.
Preferably, the average grain diameter of the boiomacromolecule nanosphere containing NADH is 500-1000nm.
The present invention also provides a kind of methods for preparing the boiomacromolecule nanosphere containing NADH comprising following step
It is rapid:
S1, by biopolymer feedstock and xanthan gum and/or sodium alginate mixed grinding, carry out physical modification, given birth to
Object macromolecule carrier；
S2, grinding NADH raw material are simultaneously sieved, and obtain NADH；
S3, the NADH, boiomacromolecule carrier are mixed and stirred for get the boiomacromolecule nanosphere containing NADH.
The present invention also provides the boiomacromolecule nanospheres described in one kind containing NADH in preparation prevention and treatment inferior health, the medicine of tumour
Application in object and/or functional food.
The present invention also provides a kind of pharmaceutical preparations, and NADH is contained described in the claim 1-5 any one comprising effective dose
Boiomacromolecule nanosphere and pharmaceutically acceptable auxiliary material；
Preferably, the pharmaceutical preparation be selected from tablet, capsule, granule, injection, tincture, suppository, patch, pill,
One of syrup, mixture, powder, lotion, film, dripping pill；
Preferably, the pharmaceutical preparation is capsule, the capsule includes hard capsule and soft capsule.
The present invention also provides a kind of methods for preparing the pharmaceutical preparation comprising the method for preparing particle:
A, granulation auxiliary material is added in the boiomacromolecule nanosphere to described containing NADH and is stirred；
B, the particle wet feed that uniform particle diameter is made is sieved；
C, the particle wet feed is dried to get particle；
The preparation of the heretofore described boiomacromolecule nanosphere containing NADH can carry out simultaneously with the preparation of dosage form,
That is, it will be appreciated by those skilled in the art that, when NADH is mixed with the boiomacromolecule carrier, it is auxiliary that the granulation can be added
Material is stirred together for, and then the particle containing NADH is directly made.
Preferably, including by particle tabletting is carried out, tablet is made；
Preferably, including by it is particles filled enter capsule shells in, capsule is made；
Preferably, including by particle with edible oil it mixes, is filled in soft capsule shell, soft capsule is made.
Preferably, the granulation auxiliary material is microcrystalline cellulose, polyvinylpyrrolidone, sodium bicarbonate, magnesium stearate, gathers
At least one of calcium phosphate, wetting agent and adhesive.
The present invention also provides a kind of functional food, and it includes the boiomacromolecule nanospheres described in effective dose containing NADH
With acceptable auxiliary material.
The above technical solution of the present invention has the following advantages over the prior art:
(1) the boiomacromolecule nanosphere of the present invention containing NADH comprising boiomacromolecule carrier and be scattered in
NADH on the boiomacromolecule carrier.The boiomacromolecule carrier is macromolecular fibre condensate, and fiber skeleton is logical
The arrangement modes such as disorderly arranged, cross arrangement, curling arrangement are crossed, three-dimensional interpenetrating polymer network structure are constituted, so that NADH is obtained
Protection, solves the problems, such as labile after it meets light or oxygen, extends the holding time of NADH effective component, reduces preservation
Difficulty.
(2) in the boiomacromolecule nanosphere of the present invention containing NADH, most of NADH is scattered in boiomacromolecule
The inside of the three-dimensional interpenetrating polymer network of carrier, small part are carried on boiomacromolecule carrier outer surface.This three-dimensional interpenetrating polymer network knot
The boiomacromolecule carrier of structure has both bioactivity and loads the effect of NADH effective component, makes to be carried between network structure
NADH is protected, and solves the problems, such as that NADH meets gastric acid fast decoupled, is unable to give full play effectiveness, is a kind of slow with enteron aisle
The macromolecule carrier of effect is released, the diseases such as parkinsonism, Alzheimer's disease, depression, cancer is treated for NADH and provides one
The ideal pharmaceutical carrier of kind.It repairs DNA, further may be used also by sustained release NADH effective component, activation DNA repair enzyme
With the generation of pre- anti-cancer.
(3) boiomacromolecule carrier of the present invention be chitosan (also known as CS) and/or konjaku glucomannan (also known as
KGM), chitosan, konjaku glucomannan can form three-dimensional interpenetrating network of fibers, and being easy to, which is carried on NADH in network, is protected
Shield.In addition, chitosan is a kind of natural macromolecular material, there is good biological functionality and compatibility, safety and micro- life
Object degradability, and since itself has positive electricity, also have the function of antibacterial；A kind of natural macromolecule of konjaku glucomannan is solvable
Property dietary fiber, viscosity is high, water suction is more, expansion is fast, due to special glucosides bond structure, also with immunogenicity.
(4) technique of the boiomacromolecule nanosphere described in preparation of the present invention containing NADH prepares physics first and changes
Property boiomacromolecule carrier, by by biopolymer feedstock and xanthan gum and/or sodium alginate mixed grinding, will biology it is high
The truncation of molecule long-chain is the strand of moderate length.Bioabsorbable polymer material medium-chain after physical modification, is more likely formed ball
Shape particle constitutes honeycomb three-dimensional interpenetrating polymer network structure, so that being conducive to NADH small molecule is carried on network structure surfaces externally and internally.
In addition, outer surface forms the structure of similar film by the boiomacromolecule carrier of physical modification, have waterproof anti-oxidation
Effect solves the problems, such as that NADH meets light and oxygen solution, extends the NADH holding time；At grinding NADH raw material and sieving
Reason, it is tens nanometers that NADH, which is ground to partial size, is easier to the three-dimensional interpenetrating polymer network structure for making NADH enter bioabsorbable polymer material
In to being protected.
(5) the boiomacromolecule nanosphere of the present invention containing NADH can be applied to prepare tablet, granule, capsule or
Soft capsule makes NADH be protected in network by boiomacromolecule carrier first by boiomacromolecule nanosphere of the preparation containing NADH
In structure, then it is made as pharmaceutical dosage form, it is therefore prevented that the problem of NADH is decomposed, can not be absorbed by the body by gastric juice in dosage form.It is above-mentioned
In dosage form, soft capsule disperses the boiomacromolecule nanosphere containing NADH in oily phase, has completely cut off NADH and air and water
Contact, further solves the labile problem of NADH, has the longer shelf-life.
Detailed description of the invention
In order to make the content of the present invention more clearly understood, it below according to specific embodiments of the present invention and combines
Attached drawing, the present invention is described in further detail, wherein
Fig. 1 is the XRD test result of the boiomacromolecule nanosphere under different NADH contents containing NADH；
Fig. 2 is the scanning electron microscope (SEM) photograph of the boiomacromolecule nanosphere described in the embodiment of the present invention 1 containing NADH；
Fig. 3 is the scanning electron microscope (SEM) photograph of the boiomacromolecule nanosphere described in the embodiment of the present invention 1 containing NADH；
Fig. 4 is that the boiomacromolecule nanosphere described in the embodiment of the present invention 2 containing NADH is made after tablet in simulation hydrochloric acid
The release rate tendency chart of effective component after solution and simulation colon solution impregnate；
Fig. 5 is to tie after tablet is made in the boiomacromolecule nanosphere containing NADH of the embodiment of the present invention 2 in simulation
The release rate tendency chart of effective component after enteric liquid impregnates.
Specific embodiment
Embodiment 1
The present embodiment provides a kind of boiomacromolecule nanosphere containing NADH, in parts by weight, including 20 parts of biologies are high
Molecular vehicle and 1 part of NADH, the NADH are scattered on boiomacromolecule carrier, and the average grain diameter of boiomacromolecule carrier is
200-1000nm, the average grain diameter of the boiomacromolecule nanosphere containing NADH are 500-1000nm.In the present embodiment, the biology
The material of macromolecule carrier is konjaku glucomannan (KGM), and KGM is natural polymer soluble dietary fiber, which is in bee
Nest shape three-dimensional interpenetrating polymer network structure, the mesh size of network structure are tens to thousands of nanometers, and NADH is entered and born by mesh
It is loaded in KGM network of fibers surface.The boiomacromolecule nanosphere further includes auxiliary material, the auxiliary material in parts by weight, including
0.05 part of sodium alginate.Sodium alginate is a kind of natural polysaccharide, and the ability with concentrate solution, formation gel and film forming can make
Boiomacromolecule carrier outer surface forms a film structure, has the anti-oxidation effect of waterproof, avoids NADH and meets light or oxygen solution
The problem of.
The present embodiment also provides a kind of method for preparing the boiomacromolecule nanosphere containing NADH comprising following step
It is rapid:
S1, the boiomacromolecule carrier for preparing physical modification: by KGM and sodium alginate colloid mill mix grinding, make point of KGM
Subchain length reduces, molecular weight reduces, formed honeycomb three-dimensional interpenetrating polymer network structure and it is agglomerating be average grain diameter partial size be 200-
The nanosphere of 1000nm.
S2, grinding NADH raw material are simultaneously sieved, and obtain the NADH that average grain diameter is 10-100nm.
S3, NADH and the boiomacromolecule carrier that step S2 is obtained are mixed and stirred for uniformly to get containing NADH's
Boiomacromolecule nanosphere.
It should be understood that the charging sequence between the NADH and the boiomacromolecule carrier is regardless of elder generation in the present invention
Afterwards, it can be added with arbitrary charging sequence.
The present embodiment also provides a kind of pharmaceutical preparation, and the pharmaceutical preparation includes the biological high score containing NADH of effective dose
Sub- nanosphere and pharmaceutically acceptable auxiliary material, the pharmaceutical preparation can for tablet, capsule, granule, injection, tincture,
One of suppository, patch, pill, syrup, mixture, powder, lotion, film, dripping pill, in the present embodiment, the drug system
Agent is particle, and the particle is prepared via a method which:
A, granulation auxiliary material is added in the boiomacromolecule nanosphere of Xiang Han NADH and is stirred, and the granulation auxiliary material includes 10 parts
Wetting agent, 5 parts of adhesives, wherein the wetting agent is at least one of the second alcohol and water that volumetric concentration is 70%, adhesive
For the pregelatinized starch of mass concentration 5-20%, mass concentration be 10-15% starch slurry, mass concentration be 10% hydroxypropyl first
At least one of cellulose solution, in the present embodiment, wetting agent is ethyl alcohol, and adhesive is the starch slurry of mass concentration 10%.
B, it is pelletized with medium size steel wet sieving diameter, i.e., the material for having weighed weight is placed in that screen size is successively decreased from inside to outside one
Bushing screen is online, and material stays in each layer compass screen surface according to granular size respectively, obtains particle wet feed.
C, wet feed is dried, is dried in vacuo 0.5-24h at 10-50 DEG C to get the boiomacromolecule nanosphere containing NADH
Particle, in the present embodiment, drying temperature is 40 DEG C, time 3h.
It should be understood that in the present invention, between the boiomacromolecule nanosphere and the granulation auxiliary material containing NADH
Charging sequence in no particular order, can be added with arbitrary charging sequence.
The preparation of the heretofore described boiomacromolecule nanosphere containing NADH can carry out simultaneously with the preparation of dosage form,
That is, it will be appreciated by those skilled in the art that, when NADH is mixed with the boiomacromolecule carrier, it is total that granulation auxiliary material can be added
With stirring.
Boiomacromolecule nanosphere described in the present embodiment containing NADH can also be used to prepare tablet, capsule or soft capsule,
NADH effective component can be discharged after preparation oral obtained in 8-10h, before preparation 2h stopped in gastric juice and discharge effectively at
Point, rear 6-8h is stopped in small intestine and is discharged effective component.The preparation can be used as prevention and treatment human-body sub-health, tumour drug or
Pet treat drug.
The present embodiment also provides a kind of functional food comprising the boiomacromolecule nanometer containing NADH of effective dose
Ball and appropriate acceptable auxiliary material, the auxiliary material includes pectin, fumaric acid, polydextrose, maltose, phosphatide, citric acid, hydroxypropyl
At least one of base starch, lactic acid, D-sorbite, milk powder, maltodextrin.
Further, NADH raw material is prepared using following technique:
1, the crude extract or its pure enzyme of nicotinamide-nucleotide adenylyltransferase are extracted.
2, the crude extract or its pure enzyme of immobilization recombination nicotinamide-nucleotide adenylyltransferase.
3, it is catalyzed with immobilization recombination nicotinamide-nucleotide adenylyltransferase, with nicotinamide nucleotide and atriphos two
Sodium (ATP) is that substrate prepares nicotinamide adenine dinucleotide.
Specific step is as follows:
Competence bacterial cell is converted by the plasmid pRSET bmj of niacinamide-containing nucleosides adenylyl transferase gene
E.coliHB101 is cultivated 24 hours at 37 DEG C on Luriabroth (LB) plate (kanamycins containing 100mg/L).Inoculation
Individually be cloned in 5 milliliters of LB liquid mediums (kanamycins containing 100mg/L) and in 30 DEG C culture 20-24 hours.Centrifugation is received
Collect thallus, and is suspended in 1 milliliter of 100mM Tris hydrochloride buffer (pH7.5).Then ultrasonic treatment bacterial cell is used, from
The heart (10 DEG C, 17800g, 10 minutes) simultaneously collects supernatant, as thick leach protein (or crude extract).The nicotinamide riboside of recombination
Adenylyl transferase thick leach protein is heat-treated 10 minutes through 70 DEG C, is centrifuged (10 DEG C, 17800g, 10 minutes) and is collected supernatant,
As partially purified albumen.
Nicotinamide-nucleotide adenylyltransferase immobilization: take nicotinamide-nucleotide adenylyltransferase thick leach protein or part pure
The albumen of change is diluted to protein content 5- with enzyme buffer liquid (0.02MTris HCl/0.001M EDTA, pH7.0 solution) is washed
10mg/ml.Enzyme dilution and PB solution (2.0mol/L potassium dihydrogen phosphate, pH7.5) are mixed in equal volume, epoxy type is added and fixes
Change zymophore LX 3000 (10 milligrams of enzymes/gram carrier), is reacted 20 hours for 25 DEG C in shaking table (revolving speed 100rpm).Reaction is completed
Sock filtration is used afterwards, is cleaned 5-6 times with enzyme buffer liquid is washed, is obtained immobilization nicotinamide-nucleotide adenylyltransferase.
Nicotinamide adenine dinucleotide is prepared with immobilization nicotinamide-nucleotide adenylyltransferase: preparing substrate solution:
The trinosin (ATP) of nicotinamide nucleotide, 10mM containing 5mM, 100mMTris hydrochloride buffer and final concentration of
The MgCl of 10mM2, adjust pH to 7.5.1 milliliter of substrate solution is taken, 0.05 gram of immobilization nicotinamide riboside adenylyl is then added and turns
Enzyme is moved, reaction 2-20 hours is carried out in 37 DEG C.Centrifugation (10 DEG C, 17800g, 15 minutes) simultaneously collects supernatant.Pass through high pressure liquid phase
The content of nicotinamide adenine dinucleotide in chromatography (HPLC) measurement gained supernatant.The result shows that nicotinamide nucleotide turns
The conversion ratio for turning to nicotinamide adenine dinucleotide is more than 80%.
Embodiment 2
The present embodiment provides a kind of boiomacromolecule nanosphere containing NADH, in parts by weight, including 80 parts of biologies are high
Molecular vehicle and 20 parts of NADH, the NADH are scattered on boiomacromolecule carrier, and the average grain diameter of boiomacromolecule carrier is
200-1000nm, the average grain diameter of the boiomacromolecule nanosphere containing NADH are 500-1000nm.In the present embodiment, the life
The material of object macromolecule carrier is the mixing of quaternized konjaku glucomannan (QKGM) and Carboxymethyl Konjac Glucomannan (CKGM)
Object, the two mass ratio are 1:1, and above-mentioned Modified K GM is natural polymer soluble dietary fiber, and the fiber is three-dimensional mutually in honeycomb
Network structure is worn, the mesh size of network structure is tens to thousands of nanometers, and NADH is entered by mesh and is carried on KGM fiber
Network surface.
The boiomacromolecule nanosphere further includes auxiliary material, in the present embodiment, the auxiliary material in parts by weight, including 30
Part sodium alginate.
The preparation method preparation of embodiment 1 can be used in boiomacromolecule nanosphere described in the present embodiment containing NADH,
Difference is that boiomacromolecule carrier is quaternized konjaku glucomannan (QKGM) and Carboxymethyl Konjac Glucomannan (CKGM)
Mixture.
The ammonium konjaku glucomannan (QKGM) and Carboxymethyl Konjac Glucomannan (CKGM) are by konjaku glucomannan
(KGM) it is made through carboxy methylation, quaternary ammoniated processing.It can also be sweet by quaternized konjaku glucomannan (QKGM) and carboxy methyl konjaku Portugal
The NaOH of the HCl or 0.1-1mol/L of glycan (CKGM) and concentration 0.1-1mol/L are stirred together for 2-10h, reduce konjak portuguese gansu polyose
The molecular weight of sugar facilitates subsequent physical modified.
The present embodiment also provides a kind of pharmaceutical preparation, and the pharmaceutical preparation includes the biological high score containing NADH of effective dose
Sub- nanosphere and pharmaceutically acceptable auxiliary material, in the present embodiment, the pharmaceutical preparation is tablet, and the tablet passes through such as lower section
Method preparation: it is pelletized using the method for granulation described in embodiment 1, particle obtained is handled with tabletting machine then, is passed through
The parameter and pressure for adjusting compression mold, can be prepared by the tablet of aimed dia, thickness and hardness.The method of granulating of the present embodiment
The difference from embodiment 1 is that: granulation auxiliary material is different, and in the present embodiment, granulation auxiliary material includes 40 parts of adhesives, 30 parts of stearic acid
Magnesium and 30 parts of microcrystalline celluloses, wherein described adhesive is the pregelatinized starch of mass concentration 5% and mass concentration is 10%
Hydroxypropyl methylcellulose solution mixture.
Pregelatinized starch in granulation auxiliary material, not only has good disintegration, adhesive effect, also can obviously improve tabletting
Hardness, disintegration and surface brightness, it is often more important that improve dissolution rate, reduce granulation difficulty, improve particle granulating
Property and compressibility, the tablet hardness of compacting is high, embrittlement degree is small, surface is smooth.Hydroxypropyl methylcellulose is hydroxypropyl and methoxyl group
The displacement group of the derivative of cellulose mixing ether, intramolecular is ethers, tablet is used for, mainly as adhesive and disintegration
Agent improves disintegration, dissolution rate increases.Microcrystalline cellulose mobility and compressibility are good, have both bonding, lubricate and help disintegration
Can, with drug without interaction, the bright and clean beautiful, easy disintegrating of tabletting shape can be made.
The present embodiment also provides a kind of functional food comprising the boiomacromolecule nanometer containing NADH of effective dose
Ball and appropriate acceptable auxiliary material, the auxiliary material includes honey, cornstarch, corn oil, sesame oil, sucrose, vitamin C, dimension
At least one of raw element E, xylitol, gelatin.
Embodiment 3
The present embodiment provides a kind of boiomacromolecule nanosphere containing NADH, in parts by weight, including 45 parts of biologies are high
Molecular vehicle and 5 parts of NADH, the NADH are scattered on boiomacromolecule carrier, and the average grain diameter of boiomacromolecule carrier is
200-1000nm, the average grain diameter of the boiomacromolecule nanosphere containing NADH are 500-1000nm.In the present embodiment, the life
The material of object macromolecule carrier is deacetylated konjaku glucomannan (da-KGM), and above-mentioned Modified K GM is that natural polymer is soluble
Dietary fiber, the fiber are in honeycomb three-dimensional interpenetrating polymer network structure, and the mesh size of network structure is tens to thousands of nanometers,
NADH is entered by mesh and is carried on KGM network of fibers surface.
The boiomacromolecule nanosphere further includes auxiliary material, in the present embodiment, the auxiliary material in parts by weight, including 15
Part sodium alginate.
The preparation method preparation of embodiment 1 can be used in boiomacromolecule nanosphere described in the present embodiment containing NADH,
Difference is that boiomacromolecule carrier is deacetylated konjaku glucomannan (da-KGM), the deacetylated konjaku glucomannan
(da-KGM) it is made by KGM through deacetylated processing.Further include before step S1 by deacetylated konjaku glucomannan (da-KGM) with
The NaOH of the HCl or 0.1-1mol/L of concentration 0.1-1mol/L are stirred together for 2-10h, reduce the molecular weight of konjaku glucomannan,
Facilitate subsequent physical modified.
The present embodiment also provides a kind of pharmaceutical preparation, and the pharmaceutical preparation includes the biological high score containing NADH of effective dose
Sub- nanosphere and pharmaceutically acceptable auxiliary material, in the present embodiment, the pharmaceutical preparation is capsule, and the capsule is by such as
Lower section method preparation: using granulation described in embodiment 1 method pelletize, after granulation, as the method for quantitative filling will made from
Particle is fitted into commercially available edibility hard capsule shell to arrive capsule preparations.The method of granulating of the present embodiment and the area of embodiment 1
Be not: granulation auxiliary material is different, in the present embodiment, pelletizes auxiliary material in parts by weight, including 20 parts of adhesives, 0.5 part of stearic acid
Magnesium and 0.5 part of microcrystalline cellulose, 1 part of polyvinylpyrrolidone, 2 parts of sodium bicarbonates, 20 parts of wetting agents, wherein the wetting agent
For the ethyl alcohol of volumetric concentration 70%, described adhesive is the starch slurry of mass concentration 10%.
For microcrystalline cellulose in auxiliary material as filler and disintegrating agent, polyvinylpyrrolidone plays protection drug and dispersion
Effect, facilitate the release of drug.
Embodiment 4
The present embodiment provides a kind of boiomacromolecule nanosphere containing NADH, in parts by weight, including 60 parts of biologies are high
Molecular vehicle and 5.2 parts of NADH, the NADH are scattered on boiomacromolecule carrier, and the average grain diameter of boiomacromolecule carrier is
200-1000nm, the average grain diameter of the boiomacromolecule nanosphere containing NADH are 500-1000nm.In the present embodiment, the life
The material of object macromolecule carrier is konjaku glucomannan (KGM), and KGM is natural polymer soluble dietary fiber, which is in
Honeycomb three-dimensional interpenetrating polymer network structure, the mesh size of network structure are tens to thousands of nanometers, and NADH is entered simultaneously by mesh
It is carried on KGM network of fibers surface.
The boiomacromolecule nanosphere further includes auxiliary material, in the present embodiment, the auxiliary material in parts by weight, including 30
Part xanthan gum.
The preparation method preparation of embodiment 1 can be used in boiomacromolecule nanosphere described in the present embodiment containing NADH,
Difference is, further includes that the NaOH of the HCl or 0.1-1mol/L by KGM Yu concentration 0.1-1mol/L is stirred together for 2- before step S1
10h reduces the molecular weight of konjaku glucomannan, facilitates subsequent physical modified.
The present embodiment also provides a kind of pharmaceutical preparation, and the pharmaceutical preparation includes the biological high score containing NADH of effective dose
Sub- nanosphere and pharmaceutically acceptable auxiliary material, in the present embodiment, the pharmaceutical preparation is soft capsule, and the soft capsule is logical
It crosses following method preparation: being pelletized using the method for granulation described in embodiment 1, after granulation, by particle obtained and proper amount of edible
Oil, biosurfactant mixing, then encapsulate into commercially available soft capsule shell, obtain soft capsule preparation, the edible oil
It can be olive oil, sesame oil, soybean oil, corn oil, camellia oil, grape seed oil etc..The method of granulating and embodiment 1 of the present embodiment
Difference be: granulation auxiliary material is different, in the present embodiment, granulation auxiliary material in parts by weight, including 16 parts of adhesives, 2 parts of tristearin
Sour magnesium, 1 part of calcium polyphosphate, 15 parts of wetting agents, wherein the wetting agent is the ethyl alcohol of volumetric concentration 70%, and described adhesive is
The hydroxypropyl methylcellulose solution of mass concentration 10%.
Embodiment 5
The present embodiment provides a kind of boiomacromolecule nanosphere containing NADH, in parts by weight, including 40 parts of biologies are high
Molecular vehicle and 12 parts of NADH, the NADH are scattered on boiomacromolecule carrier, and the average grain diameter of boiomacromolecule carrier is
200-1000nm, the average grain diameter of the boiomacromolecule nanosphere containing NADH are 500-1000nm.In the present embodiment, the biology
The material of macromolecule carrier is konjaku glucomannan (KGM), and KGM is natural polymer soluble dietary fiber, which is in bee
Nest shape three-dimensional interpenetrating polymer network structure, the mesh size of network structure are tens to thousands of nanometers, and NADH is entered and born by mesh
It is loaded in KGM network of fibers surface.
The boiomacromolecule nanosphere further includes auxiliary material, in the present embodiment, the auxiliary material in parts by weight, including
0.05 part of xanthan gum, 13 parts of sodium alginates.
The preparation method preparation of embodiment 1 can be used in boiomacromolecule nanosphere described in the present embodiment containing NADH,
Difference is, further includes that the NaOH of the HCl or 0.1-1mol/L by KGM Yu concentration 0.1-1mol/L is stirred together for 2- before step S1
10h reduces the molecular weight of konjaku glucomannan, facilitates subsequent physical modified.
The present embodiment also provides a kind of pharmaceutical preparation, and the pharmaceutical preparation includes the biological high score containing NADH of effective dose
Sub- nanosphere and pharmaceutically acceptable auxiliary material, in the present embodiment, the pharmaceutical preparation is granule, and the granule passes through reality
Apply the preparation of method described in example 1, difference is: granulation auxiliary material is different, in the present embodiment, pelletizes auxiliary material in parts by weight, including 5
Part adhesive, 12 parts of microcrystalline celluloses, 15 parts of wetting agents, wherein the wetting agent is the second alcohol and water of volumetric concentration 70%
Mixture, described adhesive are the pregelatinized starch of mass concentration 15%.
Embodiment 6
The present embodiment provides a kind of boiomacromolecule nanosphere containing NADH, in parts by weight, including 70 parts of biologies are high
Molecular vehicle and 15 parts of NADH, the NADH are scattered on boiomacromolecule carrier, and the average grain diameter of boiomacromolecule carrier is
200-1000nm, the average grain diameter of the boiomacromolecule nanosphere containing NADH are 500-1000nm.In the present embodiment, the biology
The material of macromolecule carrier is chitosan (CS), and CS is natural macromolecular material, which has honeycomb three-dimensional interpenetrating polymer network
Structure, the mesh size of network structure are tens to thousands of nanometers, and NADH is entered by mesh and is carried on chitosan network table
Face.
The boiomacromolecule nanosphere further includes auxiliary material, in the present embodiment, the auxiliary material in parts by weight, including 15
Part xanthan gum, 24 parts of sodium alginates.
The preparation method preparation of embodiment 1 can be used in boiomacromolecule nanosphere described in the present embodiment containing NADH,
Difference is, further includes the chemical modification step that chitosan is carried out to quaternary ammoniated processing before step S1, reduces the molecule of chitosan
Amount facilitates subsequent physical modified.
The present embodiment also provides a kind of pharmaceutical preparation, and the pharmaceutical preparation includes the biological high score containing NADH of effective dose
Sub- nanosphere and pharmaceutically acceptable auxiliary material, in the present embodiment, the pharmaceutical preparation is tablet, and the tablet passes through such as lower section
Method preparation: it is pelletized using the method for granulation described in embodiment 1, particle obtained is handled with tabletting machine then, is passed through
The parameter and pressure for adjusting compression mold, can be prepared by the tablet of aimed dia, thickness and hardness, the method for granulating of the present embodiment
The difference from embodiment 1 is that: granulation auxiliary material is different, in the present embodiment, pelletizes auxiliary material in parts by weight, including 16 parts of bondings
Agent, 8 parts of microcrystalline celluloses, 10 parts of polyvinylpyrrolidones, 20 parts of sodium bicarbonates, 13 parts of wetting agents, wherein the wetting agent is
The mixture of the second alcohol and water of volumetric concentration 70%, described adhesive are the starch slurry of mass concentration 10%.
Embodiment 7
The present embodiment provides a kind of boiomacromolecule nanosphere containing NADH, in parts by weight, including 55 parts of biologies are high
Molecular vehicle and 8 parts of NADH, the NADH are scattered on boiomacromolecule carrier, and the average grain diameter of boiomacromolecule carrier is
200-1000nm, the average grain diameter of the boiomacromolecule nanosphere containing NADH are 500-1000nm.In the present embodiment, the biology
The material of macromolecule carrier is chitosan (CS), and CS is natural macromolecular material, which has honeycomb three-dimensional interpenetrating polymer network
Structure, the mesh size of network structure are tens to thousands of nanometers, and NADH is entered by mesh and is carried on chitosan network table
Face.
The boiomacromolecule nanosphere further includes auxiliary material, in the present embodiment, the auxiliary material in parts by weight, including 20
Part xanthan gum, 5 parts of sodium alginates.
The preparation method preparation of embodiment 1 can be used in boiomacromolecule nanosphere described in the present embodiment containing NADH,
Difference is that boiomacromolecule carrier is chitosan.
The present embodiment also provides a kind of pharmaceutical preparation, and the pharmaceutical preparation includes the biological high score containing NADH of effective dose
Sub- nanosphere and pharmaceutically acceptable auxiliary material, in the present embodiment, the pharmaceutical preparation is granule, and the granule passes through reality
Apply the preparation of method described in example 1, difference is: granulation auxiliary material is different, in the present embodiment, pelletizes auxiliary material in parts by weight, including 8
Part adhesive, 6 parts of microcrystalline celluloses, 4 parts of polyvinylpyrrolidones, 5 parts of sodium bicarbonates, 10 parts of magnesium stearates, 10 parts of polyphosphoric acids
Calcium, 15 parts of wetting agents, wherein the wetting agent is the mixture of the second alcohol and water of volumetric concentration 70%, and described adhesive is matter
Measure the mixture of the starch slurry of concentration 10%, the pregelatinized starch of mass concentration 15%.
Experimental example
1, there is the life containing NADH of different NADH contents (0%, 8%, 10%) by X-ray diffraction method (XRD) detection
Object high molecular nanometer sphere obtains XRD diffraction pattern as shown in Figure 1, it can be seen from the figure that the boiomacromolecule of unsupported NADH
Carrier (blank microballoon) shows the diffraction broad peak (2 angles θ are the diffraction maximum at 18 ° and 22.5 °) of polysaccharide cellulose, load
After NADH, newly there are multiple diffraction maximums, be the characteristic diffraction peak of NADH, and the nanosphere XRD diffraction maximum containing 10%NADH
Intensity is high compared with the nanosphere containing 8%NADH, further demonstrates NADH and is successfully carried on boiomacromolecule carrier.
2, pass through the shape of the boiomacromolecule nanosphere described in the scanning electron microscope test embodiment of the present invention 1 containing NADH
Looks, as a result as Figure 2-3, it is seen that bioabsorbable polymer material is in honeycomb three-dimensional interpenetrating polymer network structure.
3, tablet made from embodiment 2 is impregnated to 2h under conditions of simulation hydrochloric acid solution S GF pH=2 and then is being simulated
6h is impregnated under conditions of colon solution S CF pH=6.8, tests the release rate of the 2nd, 4,6,8h NADH respectively, test result is such as
Shown in table 1 and Fig. 4.
Table 1
| Time h | Release rate % |
| 0 | 0 |
| 2 | 1.12 |
| 4 | 20.72 |
| 6 | 50.24 |
| 8 | 90.33 |
| Surplus | 0.30 |
| Total amount | 90.63 |
4, tablet made from embodiment 2 is impregnated into 8h under conditions of simulating colon solution S CF pH=6.8, tested respectively
The release rate of 2nd, 4,6,8hNADH, test result is as shown in table 2 and Fig. 5.
Table 2
| Time h | Release rate % |
| 0 | 0 |
| 2 | 39.57 |
| 4 | 66.85 |
| 6 | 85.5 |
| 8 | 93.27 |
| Surplus | 2.10 |
| Total amount | 95.37 |
Above-mentioned test result shows in the case where simulation hydrochloric acid solution and simulation colon solution impregnate, effective in tablet obtained
Ingredient NADH can be sustained into solution, be a kind of long-acting medicament.
Obviously, the above embodiments are merely examples for clarifying the description, and does not limit the embodiments.It is right
For those of ordinary skill in the art, can also make on the basis of the above description it is other it is various forms of variation or
It changes.There is no necessity and possibility to exhaust all the enbodiments.And it is extended from this it is obvious variation or
It changes still within the protection scope of the invention.
Claims (10)
1. a kind of boiomacromolecule nanosphere containing NADH, which is characterized in that including boiomacromolecule carrier and be scattered in described
NADH on boiomacromolecule carrier.
2. the boiomacromolecule nanosphere according to claim 1 containing NADH, which is characterized in that the boiomacromolecule carries
Body is in three-dimensional net structure, and the average grain diameter of the boiomacromolecule carrier is 200-1000nm.
3. the boiomacromolecule nanosphere according to claim 1 containing NADH, which is characterized in that the boiomacromolecule carries
Body be chitosan and/or konjaku glucomannan,
Preferably, the konjaku glucomannan is that konjaku glucomannan, quaternized konjaku glucomannan, carboxy methyl konjaku Portugal are sweet poly-
At least one of sugared, deacetylated konjaku glucomannan.
4. the boiomacromolecule nanosphere according to claim 1 containing NADH, which is characterized in that in parts by weight, described
Nanosphere includes 1-20 parts of NADH, 20-80 parts of boiomacromolecule carriers,
Preferably, the nanosphere further includes auxiliary material, the auxiliary material in parts by weight, including 0.05-30 parts of sodium alginates and/or
0.05-30 parts of xanthan gum.
5. the boiomacromolecule nanosphere according to claim 1 containing NADH, which is characterized in that the biology containing NADH
The average grain diameter of high molecular nanometer sphere is 500-1000nm.
6. a kind of method for preparing the boiomacromolecule nanosphere as described in any one in claim 1-5 containing NADH, feature
It is, includes the following steps:
S1, by biopolymer feedstock and xanthan gum and/or sodium alginate mixed grinding, carry out physical modification, obtain biological height
Molecular vehicle；
S2, grinding NADH raw material are simultaneously sieved, and obtain NADH；
S3, the NADH, boiomacromolecule carrier are mixed and stirred for get the boiomacromolecule nanosphere containing NADH.
7. a kind of boiomacromolecule nanosphere as described in claim any one of 1-5 containing NADH is preparing prevention and treatment inferior health, is swelling
The drug of tumor and/or the application in functional food.
8. a kind of pharmaceutical preparation, the boiomacromolecule containing NADH described in the claim 1-5 any one comprising effective dose is received
Rice ball and pharmaceutically acceptable auxiliary material；
Preferably, the pharmaceutical preparation is selected from tablet, capsule, granule, injection, tincture, suppository, patch, pill, syrup
One of agent, mixture, powder, lotion, film, dripping pill；
Preferably, the pharmaceutical preparation is capsule, and the capsule includes hard capsule and soft capsule.
9. a kind of method for preparing pharmaceutical preparation as claimed in claim 8, which is characterized in that the method including preparing particle:
A, granulation auxiliary material is added in the boiomacromolecule nanosphere to described containing NADH and is stirred；
B, the particle wet feed that uniform particle diameter is made is sieved；
C, the particle wet feed is dried to get particle；
Preferably, including by particle tabletting is carried out, tablet is made；
Preferably, including by it is particles filled enter capsule shells in, capsule is made；
Preferably, including by particle with edible oil it mixes, is filled in soft capsule shell, soft capsule is made.
Preferably, the granulation auxiliary material is microcrystalline cellulose, polyvinylpyrrolidone, sodium bicarbonate, magnesium stearate, polyphosphoric acid
At least one of calcium, wetting agent and adhesive.
10. a kind of functional food, the boiomacromolecule containing NADH described in the claim 1-5 any one comprising effective dose is received
Rice ball and acceptable auxiliary material.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811465156.1A CN109646423A (en) | 2018-12-03 | 2018-12-03 | Boiomacromolecule nanosphere containing NADH and the preparation method and application thereof |
| PCT/CN2019/074220 WO2020113812A1 (en) | 2018-12-03 | 2019-01-31 | Nadh-containing biological high-molecular-weight nanosphere, preparation method for same, and applications thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811465156.1A CN109646423A (en) | 2018-12-03 | 2018-12-03 | Boiomacromolecule nanosphere containing NADH and the preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109646423A true CN109646423A (en) | 2019-04-19 |
Family
ID=66112735
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811465156.1A Pending CN109646423A (en) | 2018-12-03 | 2018-12-03 | Boiomacromolecule nanosphere containing NADH and the preparation method and application thereof |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN109646423A (en) |
| WO (1) | WO2020113812A1 (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109908089A (en) * | 2019-03-27 | 2019-06-21 | 泓博元生命科技（深圳）有限公司 | Nanosphere and the preparation method and application thereof containing NADH or NADPH |
| CN110339179A (en) * | 2019-05-29 | 2019-10-18 | 泓博元生命科技（深圳）有限公司 | Soft capsule and its preparation method and application containing NADH or NADPH |
| CN110354770A (en) * | 2019-07-23 | 2019-10-22 | 中国石油大学(华东) | A kind of manually photosynthetic microreactor and preparation method |
| WO2020113812A1 (en) * | 2018-12-03 | 2020-06-11 | 泓博元生命科技（深圳）有限公司 | Nadh-containing biological high-molecular-weight nanosphere, preparation method for same, and applications thereof |
| WO2021073426A1 (en) * | 2019-10-17 | 2021-04-22 | 泓博元生命科技（深圳）有限公司 | Application of nadh and salt thereof in preparation of skin pigment inhibitor |
| CN112807280A (en) * | 2021-01-07 | 2021-05-18 | 钇澜杉生物科技(北京)有限公司 | Preparation process and application of polysaccharide biopolymer coated NMN and NADH |
| CN113040311A (en) * | 2021-03-16 | 2021-06-29 | 江西省华宝孔雀食品科技发展有限公司 | PH slow-release solid microcapsule and preparation method thereof |
| CN113713082A (en) * | 2021-08-27 | 2021-11-30 | 福建医科大学 | Nano autophagy inducer for Alzheimer's disease and preparation method and application thereof |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR102020013862A2 (en) * | 2020-07-07 | 2022-01-18 | Edson Luiz Peracchi | SUBCUTANEOUS LONG-TERM REABSORBABBLE IMPLANT WITH SUSTAINED RELEASE OF PRECONCENTRATED PHARMACOLOGICALLY ACTIVE SUBSTANCE IN POLYMER FOR TREATMENT OF PARKINSON'S DISEASE |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106009066A (en) * | 2016-06-17 | 2016-10-12 | 昆明理工大学 | Method for preparing nanometer materials with konjac glucomannan and chitosan |
| US20170266218A1 (en) * | 2016-03-21 | 2017-09-21 | Steve McNerlin | Nad+ coenzyme formulation and methods of making and using the same |
| CN107970228A (en) * | 2017-11-02 | 2018-05-01 | 天津大学 | A kind of preparation method using chitosan-TPP-KGM as the nano-microcapsule of compound wall materials |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100384426C (en) * | 2003-12-05 | 2008-04-30 | 天津药物研究院 | Solid dispersion containing active component adefuwei or its salt and its preparation method |
| BRPI0713053A2 (en) * | 2006-06-30 | 2012-07-17 | Iceutica Pty Ltd | Methods for the preparation of biologically active compounds in nanoparticulate form |
| US20120160944A1 (en) * | 2009-04-24 | 2012-06-28 | Aaron Dodd | Method for the production of commercial nanoparticle and micro particle powders |
| EP2994131A1 (en) * | 2013-05-10 | 2016-03-16 | Cipla Limited | Low dose pharmaceutical composition |
| CN104095817B (en) * | 2014-07-22 | 2016-10-19 | 武汉工程大学 | A kind of Nano microsphere containing magnolol or honokiol and its preparation method and application |
| CN109172545A (en) * | 2018-10-15 | 2019-01-11 | 泓博元生命科技（深圳）有限公司 | The NADH nanosphere and its preparation process of cladding konjak glucomannan and application |
| CN109646423A (en) * | 2018-12-03 | 2019-04-19 | 泓博元生命科技（深圳）有限公司 | Boiomacromolecule nanosphere containing NADH and the preparation method and application thereof |
-
2018
- 2018-12-03 CN CN201811465156.1A patent/CN109646423A/en active Pending
-
2019
- 2019-01-31 WO PCT/CN2019/074220 patent/WO2020113812A1/en active Application Filing
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20170266218A1 (en) * | 2016-03-21 | 2017-09-21 | Steve McNerlin | Nad+ coenzyme formulation and methods of making and using the same |
| CN106009066A (en) * | 2016-06-17 | 2016-10-12 | 昆明理工大学 | Method for preparing nanometer materials with konjac glucomannan and chitosan |
| CN107970228A (en) * | 2017-11-02 | 2018-05-01 | 天津大学 | A kind of preparation method using chitosan-TPP-KGM as the nano-microcapsule of compound wall materials |
Non-Patent Citations (1)
| Title |
|---|
| MARÍA ALONSO-SANDE等: "Formation of New Glucomannan-Chitosan Nanoparticles and Study of Their Ability To Associate and Deliver Proteins", 《MACROMOLECULES》 * |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020113812A1 (en) * | 2018-12-03 | 2020-06-11 | 泓博元生命科技（深圳）有限公司 | Nadh-containing biological high-molecular-weight nanosphere, preparation method for same, and applications thereof |
| CN109908089A (en) * | 2019-03-27 | 2019-06-21 | 泓博元生命科技（深圳）有限公司 | Nanosphere and the preparation method and application thereof containing NADH or NADPH |
| CN110339179A (en) * | 2019-05-29 | 2019-10-18 | 泓博元生命科技（深圳）有限公司 | Soft capsule and its preparation method and application containing NADH or NADPH |
| WO2020238297A1 (en) * | 2019-05-29 | 2020-12-03 | 泓博元生命科技（深圳）有限公司 | Soft capsule containing nadh or nadph, preparation method therefor and application thereof |
| CN110354770A (en) * | 2019-07-23 | 2019-10-22 | 中国石油大学(华东) | A kind of manually photosynthetic microreactor and preparation method |
| WO2021073426A1 (en) * | 2019-10-17 | 2021-04-22 | 泓博元生命科技（深圳）有限公司 | Application of nadh and salt thereof in preparation of skin pigment inhibitor |
| CN112807280A (en) * | 2021-01-07 | 2021-05-18 | 钇澜杉生物科技(北京)有限公司 | Preparation process and application of polysaccharide biopolymer coated NMN and NADH |
| CN112807280B (en) * | 2021-01-07 | 2023-02-03 | 钇澜杉合成生物技术(北京)有限公司 | Preparation process and application of polysaccharide biopolymer coated NMN and NADH |
| CN113040311A (en) * | 2021-03-16 | 2021-06-29 | 江西省华宝孔雀食品科技发展有限公司 | PH slow-release solid microcapsule and preparation method thereof |
| CN113713082A (en) * | 2021-08-27 | 2021-11-30 | 福建医科大学 | Nano autophagy inducer for Alzheimer's disease and preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020113812A1 (en) | 2020-06-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109646423A (en) | Boiomacromolecule nanosphere containing NADH and the preparation method and application thereof | |
| CN109364091A (en) | Boiomacromolecule nanosphere containing NMN and the preparation method and application thereof | |
| CN103458709B (en) | Microencapsulation prebiotic substances and its manufacture method | |
| JP5826107B2 (en) | Composition for enteral administration of microorganisms | |
| KR20170040336A (en) | formulation comprising particles | |
| CN109350607A (en) | The NADH nanosphere and its preparation process of cladding konjak glucomannan and application | |
| CN101406294A (en) | Dietary fiber and method of preparing dispersible tablet | |
| CN1274298C (en) | Disintegrants for deodoring effectively and their preparation | |
| CN109172545A (en) | The NADH nanosphere and its preparation process of cladding konjak glucomannan and application | |
| CN105878197A (en) | Riociguat orally disintegrating tablet and preparation method thereof | |
| CN103861114B (en) | Functional plants matrix Capsules | |
| CN110612123A (en) | Composition for disintegrating tablet containing microfibrillar cellulose and active ingredient | |
| Nadaf et al. | Evaluation of Prosopis africana seed gum as an extended release polymer for tablet formulation | |
| CN109172544A (en) | The NMN nanosphere and its preparation process of cladding konjak glucomannan and application | |
| CN101401796A (en) | Pramipexole orally disintegrating tablets and preparation method thereof | |
| CN104069082B (en) | A kind of aspartic acid piece and preparation method thereof | |
| CN103800290B (en) | Aminoglucose hydrochloride pellet preparations and preparation method thereof | |
| CN102327266A (en) | Pharmaceutical composition containing Iloperidone and preparation method thereof | |
| AU2021102578A4 (en) | Biopolymer nanosphere containing nadh, method of preparing the same and use thereof | |
| AU2021102577A4 (en) | Biopolymer nanosphere containing nicotinamide mononucleotide, preparation method therefor and use thereof | |
| CN103599077A (en) | Freeze-dried powder of pravastatin sodium composition for injection | |
| CN101444489A (en) | Astragalus polyose pellet and preparation method thereof | |
| CN101081227B (en) | Composition of diammonium glycyrrhizinate | |
| CN103432082A (en) | Glucosamine composition and preparation method thereof | |
| CN104147012B (en) | A kind of oral disintegrated preparation containing ftorafur, Gimeracil and oteracil potassium |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40005050 Country of ref document: HK |
|
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190419 |
|
| RJ01 | Rejection of invention patent application after publication |